This study looks at whether adding sacituzumab tirumotecan to pembrolizumab after surgery can help adults with non-small cell lung cancer (NSCLC). The goal is to see if this combination works better than pembrolizumab alone in keeping cancer from coming back. Participants in the study will have had surgery but did not achieve a complete response to earlier treatments.
The trial's ID number is NCT06312137. This is a Phase 3 study, which means it is looking at how well the treatment works and how safe it is. The trial is FDA-regulated and aims to include around 780 participants.
Who can join
Adults aged 18 and older can join this study. It is open to both men and women with certain types of NSCLC that can be surgically removed. To participate, individuals must be able to have surgery and have not achieved a complete response after surgery. The trial team will check to confirm who is eligible.
Condition
Non Small Cell Lung Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed into two groups. One group will receive pembrolizumab along with sacituzumab tirumotecan. The other group will receive only pembrolizumab. Each treatment will be given through an IV, with specific schedules based on the treatment group.
Where
This trial is enrolling at 50 locations. Recruiting sites are listed first.
Accellacare of Duly ( Site 4005)
Lisle, Illinois
Recruiting
Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0027)
Minneapolis, Minnesota
Recruiting
Archbold Cancer Center ( Site 0071)
Thomasville, Georgia
Recruiting
Atlantic Health Morristown Medical Center ( Site 0077)
Morristown, New Jersey
Recruiting
Avera Cancer Institute- Research ( Site 0090)
Sioux Falls, South Dakota
Recruiting
Beverly Hills Cancer Center ( Site 0070)
Beverly Hills, California
Recruiting
Cayuga Medical Center ( Site 0086)
Ithaca, New York
Recruiting
Emory University School of Medicine-Phase I ( Site 0056)
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.